Canada markets open in 2 hours 9 minutes

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
143.15-0.82 (-0.57%)
At close: 4:00PM EDT

142.02 -1.13 (-0.79%)
Before hours: 7:21AM EDT

Full screen
Trade prices are not sourced from all markets
Previous Close143.97
Open143.74
Bid141.57 x 1200
Ask144.10 x 800
Day's Range142.92 - 144.29
52 Week Range109.16 - 157.00
Volume4,497,433
Avg. Volume5,947,333
Market Cap376.848B
Beta (5Y Monthly)0.69
PE Ratio (TTM)22.51
EPS (TTM)6.36
Earnings DateJan. 26, 2021
Forward Dividend & Yield4.04 (2.81%)
Ex-Dividend DateNov. 23, 2020
1y Target Est166.18
  • Editor's Pick
    Yahoo Finance Video

    ‘Someone, somewhere in the U.S. is getting overwhelmed’ with the rising numbers of covid cases: UC Davis Health

    Dr. David Lubarsky, UC Davis Health CEO, joins The Final Round to discuss the rise of new coronavirus cases worldwide, recent news coming out on the vaccine race, and how hospitals are preparing for a new surge.

  • Editor's Pick
    Yahoo Finance Video

    Coronavirus Latest: Tuesday, October 27

    On Tuesday, Pfizer confirmed that it enrolled 42,000 volunteers into its coronavirus vaccine trial. This comes as AstraZeneca says its vaccine demonstrated immune responses among adults and Russia begins production of its second coronavirus vaccine. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

  • AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race
    Motley Fool

    AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race

    For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.